Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally. / Zebis, Lars R; Christensen, Thomas D; Thomsen, Henrik F; Hjortdal, Vibeke E.
In: Scandinavian Cardiovascular Journal, Vol. 42, No. 3, 06.2008, p. 173-7.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Amiodarone protects diabetics and non-diabetics undergoing coronary artery bypass grafting equally
AU - Zebis, Lars R
AU - Christensen, Thomas D
AU - Thomsen, Henrik F
AU - Hjortdal, Vibeke E
PY - 2008/6
Y1 - 2008/6
N2 - OBJECTIVE: To evaluate amiodarone prophylaxis in diabetics and non-diabetics. Further to clarify whether the risk of developing atrial fibrillation is higher for diabetics than non-diabetic patients, and to evaluate whether the diabetic status has any influence on the length of in-hospital stay.DESIGN: Subgroup analysis within a randomized, controlled, double-blinded trial.RESULTS: At 30 days of follow-up atrial fibrillation was equally frequent among diabetics (22%) and non-diabetics (17%) (p =0.41). The length of in-hospital stay for diabetics was prolonged with 25% (9%; 45%). The prophylactic amiodarone was found equally efficient in diabetics and non-diabetics, as the relative risk ratios were 1.2 (0.4-5.4) and 2.0 (0.3-12.5), respectively.CONCLUSIONS: Diabetics and non-diabetics had the same effect of the amiodarone prophylaxis regime. Atrial fibrillation developed equally among diabetics and non-diabetics, but the length of stay was prolonged for diabetics.
AB - OBJECTIVE: To evaluate amiodarone prophylaxis in diabetics and non-diabetics. Further to clarify whether the risk of developing atrial fibrillation is higher for diabetics than non-diabetic patients, and to evaluate whether the diabetic status has any influence on the length of in-hospital stay.DESIGN: Subgroup analysis within a randomized, controlled, double-blinded trial.RESULTS: At 30 days of follow-up atrial fibrillation was equally frequent among diabetics (22%) and non-diabetics (17%) (p =0.41). The length of in-hospital stay for diabetics was prolonged with 25% (9%; 45%). The prophylactic amiodarone was found equally efficient in diabetics and non-diabetics, as the relative risk ratios were 1.2 (0.4-5.4) and 2.0 (0.3-12.5), respectively.CONCLUSIONS: Diabetics and non-diabetics had the same effect of the amiodarone prophylaxis regime. Atrial fibrillation developed equally among diabetics and non-diabetics, but the length of stay was prolonged for diabetics.
KW - Aged
KW - Amiodarone/administration & dosage
KW - Anti-Arrhythmia Agents/administration & dosage
KW - Atrial Fibrillation/etiology
KW - Coronary Artery Bypass/adverse effects
KW - Coronary Artery Disease/drug therapy
KW - Diabetes Mellitus/drug therapy
KW - Double-Blind Method
KW - Drug Administration Schedule
KW - Female
KW - Humans
KW - Length of Stay
KW - Male
KW - Middle Aged
KW - Risk Assessment
KW - Time Factors
KW - Treatment Outcome
U2 - 10.1080/14017430701798820
DO - 10.1080/14017430701798820
M3 - Journal article
C2 - 18569948
VL - 42
SP - 173
EP - 177
JO - Scandinavian Cardiovascular Journal
JF - Scandinavian Cardiovascular Journal
SN - 1401-7458
IS - 3
ER -
ID: 242714805